Figure 1.

Full dosing classification of qualifying antihypertensive medications. Justification for full dosing was documented using the following categories: (1) clinical judgment of the principle investigator (PI); (2) highest dose previously tolerated by that patient; (3) highest dose listed in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7); or (4) highest available dose (ie, listed in the manufacturer's label or Physicians Desk Reference). For patients who qualified for study entry using each class of drugs shown ( Table I ), percent of patients in each full‐dose category are displayed. ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; BB, β‐blocker.